Dr. Jason Coloma is the CEO of Maze Therapeutics. Prior to his appointment to CEO, he was a venture partner at Third Rock Ventures, where he was instrumental in the founding and launch of the company. Previously, he held a number of roles at Roche, including vice president & global therapeutic area head of oncology and cancer immunotherapy partnering. Before joining Roche, Jason was a consultant in the life sciences practice at L.E.K. Consulting. He also worked in finance at Amgen and in research at the University of California, San Francisco and Cytokinetics. Jason holds a Ph.D. and M.P.H. at the University of California, Berkeley, an MBA from the Tuck School of Business at Dartmouth and a B.S. in biology from the University of San Francisco.
Track Chair: Sharon Benzeno, Adaptive Biotechnologies